Navigation Links
Reportlinker Adds US Vaccines Market

NEW YORK, Sept. 7 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

US Vaccines Market

US demand to grow 5.5% annually through 2014Demand for vaccines is forecast to increase 5.5 percent annually to more than $14 billion in 2014. The market has experienced dramatic growth due to increasing routine seasonal influenza immunization and the rising number of preventive and booster vaccines available for adults and adolescents. This growth will be compounded as several new therapeutic vaccines for cancer reach the market, followed in the coming years by biological treatments for Respiratory Syncytial Virus (RSV) and Alzheimer's Disease, and a variety of new vaccines for travel and biodefense.

New routine vaccines to boost adult, adolescent segmentPediatric vaccines have been the mainstay of the vaccine market for many years, growing steadily as new products emerged and as a greater number of routine vaccinations were encouraged. Now, a substantial number of primary vaccines and boosters are being recommended for adolescents and older adults, and the market for vaccines has expanded dramatically with the addition of these populations to the target markets for vaccine producers. Significant growth in the market has been fueled by the introduction of a vaccine for Human Papillomavirus (HPV), recommended for girls and young women and now being considered for males and a wider age range. Seasonal influenza vaccination is also gaining ground and represents a substantial portion of growth in adult vaccines, as new preventive treatments against zoster and meningococcal disease. Also a factor in adult vaccines is the growing use of boosters against tetanus, diphtheria, pertussis and other diseases.

Combination vaccines to pace pediatric productsAmong vaccines for children, sales will be affected by the expiration of patent protection for many of the most widely used vaccines. This has encouraged producers to develop several new combination vaccines, which will serve to maintain the value of products while decreasing the burden of multiple individual injections. Traditional DTaP (diphtheria, tetanus, pertussis) vaccines are being supplemented by products for Hepatitis B and polio or Haemophilus b. Also being developed are vaccines to address a wider range of bacterial serotypes, as with Wyeth's blockbuster PREVNAR7, which has been expanded to address 13 serotypes and which is recommended as a supplement for children who already received the earlier vaccine. Relatively new vaccines, such as that for Rotavirus, continue to mature and to reach greater immunization coverage.

Many new therapeutic vaccines showing promiseVaccine demand will be spurred considerably by a number of therapeutic vaccines for cancer that are nearing completion of clinical trials and are poised for FDA approval. There are currently 50 cancer vaccines in phase III or later trials, and the activity surrounding cancer vaccine development is expected to continue at a high pace. Also showing promise are vaccines being developed for RSV, HIV and Alzheimer's Disease. Similarly, a range of vaccines for travel, developing countries and biodefense are in the pipeline, including prophylactics for malaria, hemorrhagic fevers, West Nile virus and plague.

Study coverageThis new industry study presents historical demand data (1999, 2004 and 2009) plus forecasts for 2014 and 2019 by major and minor product group. The study also considers market environment factors, details industry structure, evaluates company market share and profiles 17 industry participants.


Macroeconomic Outlook 5

Demographic Patterns 8

Health Care Trends 11

Health Insurance & Reimbursement 12

Medical Conditions 14

Chronic Conditions 15

Acute Conditions 17

Reportable Diseases 19

National Health Expenditures 22

Medical Facilities & Professionals 24

Patient Activity 27

Animal Health Care 30

Animal Demographic Trends 31

Veterinarians & Other Veterinary Workers 32

Animal Health Expenditures 33

Regulatory Considerations 36

Human Vaccines Regulation 36

Animal Vaccines Regulation 38


Technologies Used in Currently Licensed Products 40

Technologies Under Development 44

Delivery 45

Valence & Combined Vaccines 46

Efficacy 47


Major Product Groups 50

Human Vaccines 51

Recommended Childhood Immunizations 54

Recommended Adult & Adolescent Immunizations 55

Animal Vaccines 57

Historical Market Trends 58

International Activity & Foreign Trade 59

Human Vaccines Trade 62

Animal Vaccines Trade 63

V. HUMAN VACCINES 65General 65

Pediatric Vaccines 67

Combination Vaccines 69

Diphtheria-Tetanus-Pertussis (DTaP) 70

Measles-Mumps-Rubella (MMR) 72

Other Combination Vaccines 75

Pneumococcal (PCV) 76

Varicella 78

Rotavirus 80

Hepatitis 82

Haemophilus b (Hib) 84

Pediatric Seasonal Influenza 86

Polio 88

Adult & Adolescent Vaccines 89

Seasonal Influenza Vaccines 91

Human Papillomavirus 95

Tetanus-Diphtheria-Pertussis (Tdap) 97

Meningococcus 99

Pneumococcus 101

Hepatitis 103

Herpes Zoster 104

Other Adult & Adolescent Vaccines 106

Varicella 107

Tuberculosis 108

Lyme Disease 109

Pandemic Influenza Vaccines 110

Biodefense 113

Anthrax 115

Smallpox 117

Travel Vaccines 119

Developmental Vaccines 125

Cancer 127

Prostate Cancer 129

Lung Cancer 130

Other Cancers 131

Other Developmental Vaccines 132


Respiratory Syncytial Virus (RSV) 135

Alzheimer's Disease 137

All Other Developmental Vaccines 138

VI. ANIMAL VACCINES 140General 140

Livestock Vaccines 142

Bovine Vaccines 143

Porcine Vaccines 146

Ovine Vaccines 148

Companion Animal Vaccines 149

Canine Vaccines 151

Feline Vaccines 152

Equine Vaccines 153

Other Companion Animal Vaccines 155

Poultry Vaccines 155

Other Animal Vaccines 158


Market Share 162

Competitive Strategies 164

Mergers & Acquisitions 166

Licensing & Related Agreements 168

Research & Development 173

Manufacturing 174

Marketing & Distribution 175

Company Profiles 177

AstraZeneca plc 178

Baxter International Incorporated 180

Biogen Idec Incorporated 182

Boehringer Ingelheim GmbH 183

Crucell NV 185

Dow Chemical Company 190

DynPort Vaccine Company LLC 192

Emergent BioSolutions Incorporated 194

GenVec Incorporated 197

GlaxoSmithKline plc 199

Heska Corporation 202

Intervet/Schering-Plough Animal Health, see Merck

MedImmune LLC, see AstraZeneca

Merck & Company Incorporated 204

Merial Limited, see Sanofi-Aventis

Novartis AG 210

Pfizer Incorporated 214

PharmAthene Incorporated 218

Sanofi-Aventis 221

VaxGen Incorporated 227

VaxInnate Corporation 229

Wyeth, see Pfizer

Additional Companies Mentioned in the Study 231


2 Population & Households 11

3 Health Insurance Coverage of the US Population 14

4 Chronic Conditions by Type 17

5 Acute Conditions by Type 19

6 Specified Reportable Diseases 21

7 National Health Expenditures 24

8 Selected Medical Facilities & Professionals 27

9 Patient Activity 30

10 Animal Population 32

11 Animal Health Employment 33

12 Animal Health Expenditures 35

SECTION III -- VACCINE TECHNOLOGIES1 US Licensed Vaccines by Production Technology 42SECTION IV -- PRODUCT OVERVIEW1 Vaccines Demand by Major Product Group 51

2 Human Vaccines Licensed for US Sale 52

3 2010 CDC-Recommended Childhood Immunizations 55

4 2010 CDC-Recommended Adolescent Immunizations 56

5 2010 CDC-Recommended Adult Immunizations 56

6 Vaccines Market, 1999-2009 59

7 US Trade in Vaccines 62

8 US Trade in Human Vaccines 63

9 US Trade in Animal Vaccines 64

SECTION V -- HUMAN VACCINES1 Human Vaccines Demand 67

2 Pediatric Vaccines Demand by Type 69

3 Pediatric Combination Vaccines Demand 70

4 Diphtheria, Tetanus & Pertussis (DTaP)

Combination Vaccines Demand 72

5 Measles, Mumps & Rubella (MMR)

Combination Vaccines Demand 75

6 Other Combination Vaccines Demand 76

7 Pediatric Pneumococcal Vaccines Demand 78

8 Varicella Vaccines Demand 80

9 Rotavirus Vaccines Demand 82

10 Pediatric Hepatitis A & B Vaccines Demand 84

11 Haemophilus b (Hib) Vaccines Demand 86

12 Pediatric Seasonal Influenza Vaccines Demand 88

13 Polio Vaccines Demand 89

14 Adult & Adolescent Vaccines Demand by Group & Condition 91

15 Adult & Adolescent Seasonal Influenza Vaccines Demand 95

16 Human Papillomavirus (HPV) Vaccines Demand 97

17 Tetanus-Diphtheria-Pertussis (Tdap) Vaccines Demand 99

18 Meningococcal Vaccines Demand 101

19 Adult & Adolescent Pneumococcal Vaccines Demand 103

20 Adult & Adolescent Hepatitis A & B Vaccines Demand 104

21 Herpes Zoster Vaccines Demand 106

22 Other Adult & Adolescent Vaccines Demand 107

23 Pandemic Influenza Vaccines Demand 113

24 Biodefense Vaccines Demand 115

25 Travel Vaccines Demand 120

26 Developmental Vaccines Demand 127

27 Cancer Vaccines Demand 129

28 Other Developmental Vaccines Demand 133

SECTION VI -- ANIMAL VACCINES1 Animal Vaccines Demand 141

2 Livestock Vaccines 143

3 Companion Animal Vaccines Demand 150

4 Poultry Vaccines Demand 158

5 Other Animal Vaccines Demand 159

SECTION VII -- INDUSTRY STRUCTURE1 US Vaccines Revenues by Company, 2009 161

2 Selected Acquisitions & Divestitures 167

3 Selected Cooperative Agreements 171

LIST OF CHARTSSECTION VII -- INDUSTRY STRUCTURE1 US Human Vaccines Market Share by Company, 2009 162

2 US Animal Vaccines Market Share by Company, 2009 163

To order this report:Biotechnology Industry: US Vaccines Market

Biotechnology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:  Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
2. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
3. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
4. Reportlinker Adds Proteomics: Technologies and Global Markets Report
5. Reportlinker Adds Nanomedicine Report
6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
7. Reportlinker Adds Nanoporous Materials Report
8. Reportlinker Adds Membrane Bioreactors Report
9. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
10. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
11. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
Post Your Comments:
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
Breaking Biology Technology:
(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/11/2015)... 2015   MedNet Solutions , an innovative SaaS-based eClinical ... is pleased to announce that it will be a Sponsor ... event, to be held November 17-19 in Hamburg ... demonstrations of iMedNet , MedNet,s easy-to-use, proven ... has been able to deliver time and cost savings ...
Breaking Biology News(10 mins):